AnaptysBio/ANAB

$26.47

0.03%
-
1D1W1MYTD1YMAX

About AnaptysBio

AnaptysBio, Inc. is a clinical-stage biotechnology company that delivers immunology therapeutics. It is focused on developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases. Its product candidate pipeline includes Rosnilimab, which is designed to suppress aberrant T cell driven inflammation by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; ANB032, which is designed to augment BTLA signaling that is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation; ANB033, which targets CD122, the common beta subunit shared by the IL-15 and IL-2 receptors; Imsidolimab, which inhibits the interleukin-36 receptor (IL-36R) and is developed for the treatment of generalized pustular psoriasis (GPP), and Etokimab, which inhibits IL-33 function and acts upstream of key cell types involved in atopy and the subsequent release of Th2 cytokines.

Ticker

ANAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel Faga

Employees

96

Headquarters

San diego, United States

AnaptysBio Metrics

BasicAdvanced
$703.18M
Market cap
-
P/E ratio
-$5.41
EPS
-0.26
Beta
-
Dividend rate

What the Analysts think about AnaptysBio

Analyst Ratings

Majority rating from 7 analysts.
Hold

Price Targets

Average projection from 8 analysts.
51.11% upside
High $80.00
Low $20.00
$26.47
Current price
$40.00
Average price target

AnaptysBio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,130.3% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$3.3M
-2.94%
Net income
$-37.3M
-6.28%
Profit margin
-1,130.3%
-3.44%

AnaptysBio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 21.4%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.93
-$1.58
-$1.50
-$1.41
-
Expected
-$0.96
-$1.05
-$1.70
-$1.79
-$1.60
Surprise
-2.84%
50.76%
-11.63%
-21.4%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell AnaptysBio stock

Buy or sell AnaptysBio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing